There are no clinical tools to functionally assess degree of DNA damage in breast cancer. The comet assay is an accepted research tool for assessing DNA damage, however, most cancer studies have assessed lymphocytes as surrogate cells. The aim of this pilot study was to use the comet assay in early breast cancer directly in tumor tissue to compare DNA damage between and within traditionally defined subgroups, and to explore intra-tumoral heterogeneity. Scrapings of tumor and healthy breast tissue were obtained at primary surgery from 104 women. Comet assay was applied to quantitatively assess DNA damage, revealing substantial inter- and intra-subgroup variation. Marked intra-tumoral heterogeneity was evident across all subgroups. The degree of DNA damage for an individual could not be predicted by breast cancer subgroup. Comet assay warrants further study as a potential clinical tool for identification of tumoral DNA damage and ultimately, individualised use of DNA damaging therapy.

Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients / Galardi, F.; Oakman, C.; Truglia, M. C.; Cappadona, S.; Biggeri, Annibale; Grisotto, Laura; Giovannelli, Lisa; Bessia, S.; Giannini, A.; Biganzoli, L.; Santarpia, L.; Di Leo, A.. - In: THE BREAST. - ISSN 0960-9776. - STAMPA. - 21:(2012), pp. 336-342. [10.1016/j.breast.2012.02.007]

Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients

BIGGERI, ANNIBALE;GRISOTTO, LAURA;GIOVANNELLI, LISA;
2012

Abstract

There are no clinical tools to functionally assess degree of DNA damage in breast cancer. The comet assay is an accepted research tool for assessing DNA damage, however, most cancer studies have assessed lymphocytes as surrogate cells. The aim of this pilot study was to use the comet assay in early breast cancer directly in tumor tissue to compare DNA damage between and within traditionally defined subgroups, and to explore intra-tumoral heterogeneity. Scrapings of tumor and healthy breast tissue were obtained at primary surgery from 104 women. Comet assay was applied to quantitatively assess DNA damage, revealing substantial inter- and intra-subgroup variation. Marked intra-tumoral heterogeneity was evident across all subgroups. The degree of DNA damage for an individual could not be predicted by breast cancer subgroup. Comet assay warrants further study as a potential clinical tool for identification of tumoral DNA damage and ultimately, individualised use of DNA damaging therapy.
2012
21
336
342
Galardi, F.; Oakman, C.; Truglia, M. C.; Cappadona, S.; Biggeri, Annibale; Grisotto, Laura; Giovannelli, Lisa; Bessia, S.; Giannini, A.; Biganzoli, L....espandi
File in questo prodotto:
File Dimensione Formato  
Galardi et al TheBreast 2012.pdf

Accesso chiuso

Tipologia: Versione finale referata (Postprint, Accepted manuscript)
Licenza: Tutti i diritti riservati
Dimensione 704.26 kB
Formato Adobe PDF
704.26 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/648765
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 11
social impact